News

Public · Published

Piramal Pharma Q2 Results: Firm swings to profit as revenue jumps 28%, led by CDMO growth

Piramal Pharma reported a net profit of ₹5.58 crore for Q2 FY27, compared with a ₹99.2 crore loss a year earlier. Revenue rose 28% to ₹2,617 crore, and EBITDA margin expanded to 13.3% from 7.8%.

Published:

Updated:

What happened

Piramal Pharma reported a net profit of ₹5.58 crore for Q2 FY27, compared with a ₹99.2 crore loss a year earlier. Revenue rose 28% to ₹2,617 crore, and EBITDA margin expanded to 13.3% from 7.8%.

Confirmed

Global impact / market context

The swing to profit shows the company earned more profit per sale as revenue grew, helped by higher use of its facilities and cost savings. That combination can support internally funded capital spending and reduce reliance on borrowed money.

Analyst inference

Piramal Pharma upgraded its FY27 outlook to 19% to 20% revenue growth with meaningfully higher profitability, citing first-half momentum. This suggests management expects the demand and cost trends behind the quarter to continue through the year.

Analyst inference

What to watch

  1. Piramal Pharma added 22 new customers and hosted 110 customer audits in the first half, while completing 12 regulatory inspections with no Official Action Indicated classifications. Confirmed
  2. Track whether the upgraded FY27 revenue growth guidance of 19% to 20%, alongside meaningfully higher profitability, is actually delivered in the coming quarters. Proposed
  3. Watch whether higher capacity utilisation and cost optimisation keep expanding profit per sale; if they fade, the earnings improvement could slow even if revenue still grows. Analyst inference

Evidence

  • Original source link unavailable